FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2073916739> ?p ?o ?g. }

• W2073916739 endingPage "1099" @default.
• W2073916739 startingPage "1095" @default.
• W2073916739 abstract "Background Inhibition of the renin-angiotensin system is a widely accepted approach to treat immunoglobulin A (IgA) nephropathy, whereas the role of fish oils as a supplement is controversial. Tumor necrosis factor α (TNF-α) is considered to be involved in the pathophysiologic process of this disorder. Recent in vitro and clinical observations that wormwood can decrease TNF-α levels has led us to investigate the effect of wormwood as a supplement in patients with IgA nephropathy. Study Design Pilot uncontrolled trial. Setting & Participants 10 patients with biopsy-proven IgA nephropathy, normal kidney function, and a history of at least 3 months of proteinuria with protein excretion >500 mg/d and <3,500 mg/d despite ongoing dual renin-angiotensin system blockade. Intervention The selected patients were given supplements of 1.8 g/d of thujone-free wormwood preparation for 6 months without discontinuing their renin-angiotensin system blockade. Outcomes Proteinuria and blood pressure after intervention compared with baseline values. Measurements Monthly assessment of urine protein-creatinine ratio and blood pressure during the observation period. Results Urine protein-creatinine ratio decreased significantly from 2,340 ± 530 to 315 ± 200 mg/g at the end of the supplementation period (P < 0.001) and was stable during the supplement-free follow-up of another 6 months. Estimated glomerular filtration rate and endogenous creatinine clearance were unchanged during the entire study period. There was a moderate, but significant, decrease (P < 0.002) in mean arterial blood pressure. Limitations Open uncontrolled trial including a small number of patients. Conclusions Thujone-free wormwood with its favorable safety profile can be an alternative supplement to manage proteinuria in patients with IgA nephropathy. Inhibition of the renin-angiotensin system is a widely accepted approach to treat immunoglobulin A (IgA) nephropathy, whereas the role of fish oils as a supplement is controversial. Tumor necrosis factor α (TNF-α) is considered to be involved in the pathophysiologic process of this disorder. Recent in vitro and clinical observations that wormwood can decrease TNF-α levels has led us to investigate the effect of wormwood as a supplement in patients with IgA nephropathy. Pilot uncontrolled trial. 10 patients with biopsy-proven IgA nephropathy, normal kidney function, and a history of at least 3 months of proteinuria with protein excretion >500 mg/d and <3,500 mg/d despite ongoing dual renin-angiotensin system blockade. The selected patients were given supplements of 1.8 g/d of thujone-free wormwood preparation for 6 months without discontinuing their renin-angiotensin system blockade. Proteinuria and blood pressure after intervention compared with baseline values. Monthly assessment of urine protein-creatinine ratio and blood pressure during the observation period. Urine protein-creatinine ratio decreased significantly from 2,340 ± 530 to 315 ± 200 mg/g at the end of the supplementation period (P < 0.001) and was stable during the supplement-free follow-up of another 6 months. Estimated glomerular filtration rate and endogenous creatinine clearance were unchanged during the entire study period. There was a moderate, but significant, decrease (P < 0.002) in mean arterial blood pressure. Open uncontrolled trial including a small number of patients. Thujone-free wormwood with its favorable safety profile can be an alternative supplement to manage proteinuria in patients with IgA nephropathy." @default.
• W2073916739 created "2016-06-24" @default.
• W2073916739 creator A5012419218 @default.
• W2073916739 creator A5035136537 @default.
• W2073916739 creator A5044253645 @default.
• W2073916739 creator A5064278810 @default.
• W2073916739 date "2010-12-01" @default.
• W2073916739 modified "2023-09-26" @default.
• W2073916739 title "Wormwood (Artemisia absinthium) for Poorly Responsive Early-Stage IgA Nephropathy: A Pilot Uncontrolled Trial" @default.
• W2073916739 cites W1692925935 @default.
• W2073916739 cites W1971577009 @default.
• W2073916739 cites W2002839070 @default.
• W2073916739 cites W2020498525 @default.
• W2073916739 cites W2022916616 @default.
• W2073916739 cites W2047640970 @default.
• W2073916739 cites W2094144275 @default.
• W2073916739 cites W2111533861 @default.
• W2073916739 cites W2117649235 @default.
• W2073916739 cites W2123917517 @default.
• W2073916739 cites W2147953447 @default.
• W2073916739 cites W2148510550 @default.
• W2073916739 cites W2149140447 @default.
• W2073916739 cites W2168065965 @default.
• W2073916739 doi "https://doi.org/10.1053/j.ajkd.2010.06.025" @default.
• W2073916739 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20843592" @default.
• W2073916739 hasPublicationYear "2010" @default.
• W2073916739 type Work @default.
• W2073916739 sameAs 2073916739 @default.
• W2073916739 citedByCount "17" @default.
• W2073916739 countsByYear W20739167392012 @default.
• W2073916739 countsByYear W20739167392013 @default.
• W2073916739 countsByYear W20739167392014 @default.
• W2073916739 countsByYear W20739167392016 @default.
• W2073916739 countsByYear W20739167392019 @default.
• W2073916739 countsByYear W20739167392020 @default.
• W2073916739 countsByYear W20739167392022 @default.
• W2073916739 crossrefType "journal-article" @default.
• W2073916739 hasAuthorship W2073916739A5012419218 @default.
• W2073916739 hasAuthorship W2073916739A5035136537 @default.
• W2073916739 hasAuthorship W2073916739A5044253645 @default.
• W2073916739 hasAuthorship W2073916739A5064278810 @default.
• W2073916739 hasConcept C10146269 @default.
• W2073916739 hasConcept C126322002 @default.
• W2073916739 hasConcept C126894567 @default.
• W2073916739 hasConcept C134018914 @default.
• W2073916739 hasConcept C159641895 @default.
• W2073916739 hasConcept C2779561371 @default.
• W2073916739 hasConcept C2780091579 @default.
• W2073916739 hasConcept C2780306776 @default.
• W2073916739 hasConcept C2781184683 @default.
• W2073916739 hasConcept C555293320 @default.
• W2073916739 hasConcept C71924100 @default.
• W2073916739 hasConcept C84393581 @default.
• W2073916739 hasConcept C90924648 @default.
• W2073916739 hasConceptScore W2073916739C10146269 @default.
• W2073916739 hasConceptScore W2073916739C126322002 @default.
• W2073916739 hasConceptScore W2073916739C126894567 @default.
• W2073916739 hasConceptScore W2073916739C134018914 @default.
• W2073916739 hasConceptScore W2073916739C159641895 @default.
• W2073916739 hasConceptScore W2073916739C2779561371 @default.
• W2073916739 hasConceptScore W2073916739C2780091579 @default.
• W2073916739 hasConceptScore W2073916739C2780306776 @default.
• W2073916739 hasConceptScore W2073916739C2781184683 @default.
• W2073916739 hasConceptScore W2073916739C555293320 @default.
• W2073916739 hasConceptScore W2073916739C71924100 @default.
• W2073916739 hasConceptScore W2073916739C84393581 @default.
• W2073916739 hasConceptScore W2073916739C90924648 @default.
• W2073916739 hasIssue "6" @default.
• W2073916739 hasLocation W20739167391 @default.
• W2073916739 hasLocation W20739167392 @default.
• W2073916739 hasOpenAccess W2073916739 @default.
• W2073916739 hasPrimaryLocation W20739167391 @default.
• W2073916739 hasRelatedWork W179186690 @default.
• W2073916739 hasRelatedWork W2013701055 @default.
• W2073916739 hasRelatedWork W2031694281 @default.
• W2073916739 hasRelatedWork W2057561566 @default.
• W2073916739 hasRelatedWork W2377006731 @default.
• W2073916739 hasRelatedWork W2800811471 @default.
• W2073916739 hasRelatedWork W2916219914 @default.
• W2073916739 hasRelatedWork W4235119269 @default.
• W2073916739 hasRelatedWork W593504957 @default.
• W2073916739 hasRelatedWork W2150504458 @default.
• W2073916739 hasVolume "56" @default.
• W2073916739 isParatext "false" @default.
• W2073916739 isRetracted "false" @default.
• W2073916739 magId "2073916739" @default.
• W2073916739 workType "article" @default.